263 related articles for article (PubMed ID: 32950684)
1. Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease.
Cavagnero KJ; Doherty TA
Ann Allergy Asthma Immunol; 2021 Feb; 126(2):135-142. PubMed ID: 32950684
[TBL] [Abstract][Full Text] [Related]
2. Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD.
Badrani JH; Cavagnero K; Eastman JJ; Kim AS; Strohm A; Yan C; Deconde A; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2023 Nov; 152(5):1330-1335.e1. PubMed ID: 37543185
[TBL] [Abstract][Full Text] [Related]
3. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
Eastman JJ; Cavagnero KJ; Deconde AS; Kim AS; Karta MR; Broide DH; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2017 Jul; 140(1):101-108.e3. PubMed ID: 28279492
[TBL] [Abstract][Full Text] [Related]
4. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.
White AA; Doherty TA
Am J Rhinol Allergy; 2018 Jan; 32(1):7-11. PubMed ID: 29336282
[TBL] [Abstract][Full Text] [Related]
5. Aspirin-exacerbated respiratory disease.
Wangberg H; White AA
Curr Opin Immunol; 2020 Oct; 66():9-13. PubMed ID: 32299015
[TBL] [Abstract][Full Text] [Related]
6. Cytokine and Lipid Mediator Regulation of Group 2 Innate Lymphoid Cells (ILC2s) in Human Allergic Airway Disease.
Cavagnero K; Doherty TA
J Cytokine Biol; 2017 Aug; 2(2):. PubMed ID: 28959799
[TBL] [Abstract][Full Text] [Related]
7. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease.
Scott WC; Cahill KN; Milne GL; Li P; Sheng Q; Huang LC; Dennis S; Snyder J; Bauer AM; Chandra RK; Chowdhury NI; Turner JH
J Allergy Clin Immunol; 2021 Apr; 147(4):1318-1328.e5. PubMed ID: 33189729
[TBL] [Abstract][Full Text] [Related]
9. Group 2 innate lymphoid cells in nasal polyposis.
Stevens WW; Kato A
Ann Allergy Asthma Immunol; 2021 Feb; 126(2):110-117. PubMed ID: 32781240
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells.
Rusznak M; Peebles RS
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):38-45. PubMed ID: 30516547
[TBL] [Abstract][Full Text] [Related]
11. Cellular interactions in aspirin-exacerbated respiratory disease.
Badrani JH; Doherty TA
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):65-70. PubMed ID: 33306487
[TBL] [Abstract][Full Text] [Related]
12. Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.
Eid R; Yan CH; Stevens W; Doherty TA; Borish L
J Allergy Clin Immunol; 2021 Aug; 148(2):309-318. PubMed ID: 34364539
[TBL] [Abstract][Full Text] [Related]
13. [Advances in aspirin-exacerbated respiratory disease (AERD)].
Higashi N; Mitsui C; Taniguchi M
Nihon Rinsho; 2016 Oct; 74(10):1683-1687. PubMed ID: 30551280
[TBL] [Abstract][Full Text] [Related]
14. Update on Aspirin-Exacerbated Respiratory Disease.
Woessner KM
Curr Allergy Asthma Rep; 2017 Jan; 17(1):2. PubMed ID: 28097500
[TBL] [Abstract][Full Text] [Related]
15. Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
Laidlaw TM; Boyce JA
J Allergy Clin Immunol; 2023 Feb; 151(2):301-309. PubMed ID: 36184313
[TBL] [Abstract][Full Text] [Related]
16. Platelets in patients with aspirin-exacerbated respiratory disease.
Laidlaw TM; Boyce JA
J Allergy Clin Immunol; 2015 Jun; 135(6):1407-14; quiz 1415. PubMed ID: 26051947
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
Foer D; Amin T; Nagai J; Tani Y; Feng C; Liu T; Newcomb DC; Lai J; Hayashi H; Snyder WE; McGill A; Lin A; Laidlaw TM; Niswender KD; Boyce JA; Cahill KN
J Immunol; 2023 Dec; 211(12):1806-1813. PubMed ID: 37870292
[TBL] [Abstract][Full Text] [Related]
18. Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
Liu T; Kanaoka Y; Barrett NA; Feng C; Garofalo D; Lai J; Buchheit K; Bhattacharya N; Laidlaw TM; Katz HR; Boyce JA
J Immunol; 2015 Oct; 195(8):3537-45. PubMed ID: 26342029
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of NSAID-induced reactions in aspirin-exacerbated respiratory disease.
Laidlaw TM
World J Otorhinolaryngol Head Neck Surg; 2018 Sep; 4(3):162-168. PubMed ID: 30506046
[TBL] [Abstract][Full Text] [Related]
20. Association of interleukin-25 levels with development of aspirin induced respiratory diseases.
Lee JU; Chang HS; Lee HJ; Bae DJ; Son JH; Park JS; Choi JS; Hwang HG; Park CS
Respir Med; 2017 Feb; 123():71-78. PubMed ID: 28137499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
